Breaking News: GSK plc Investors Encouraged to Join Securities Fraud Class Action Lawsuit
LOS ANGELES, CA – Glancy Prongay & Murray LLP, a leading national shareholder rights law firm, announced today that investors who suffered losses in GSK plc (“GSK” or the “Company”) (NYSE: GSK) securities between December 19, 2020, and March 24, 2025, have the opportunity to lead the securities fraud class action lawsuit against the pharmaceutical giant. The lawsuit alleges that GSK made false and misleading statements and failed to disclose material information concerning the Company’s financial condition and business operations.
Background on GSK plc
GSK is a global healthcare company that researches, develops, manufactures, and sells pharmaceuticals, vaccines, and consumer healthcare products. The Company’s portfolio includes a wide range of therapeutic areas, such as respiratory, oncology, HIV, vaccines, and rare diseases. GSK employs over 100,000 people worldwide and generates annual revenues of approximately £33 billion ($44 billion).
Allegations of Securities Fraud
The class action lawsuit alleges that GSK and certain of its executives made false and misleading statements and failed to disclose material information regarding the Company’s financial condition and business operations. Specifically, the complaint alleges that:
- GSK failed to disclose that certain of its drugs, including its blockbuster drug, Shingrix, were experiencing declining sales,
- GSK failed to disclose that certain of its clinical trials for potential new drugs were not progressing as planned,
- GSK failed to disclose that its restructuring efforts were not yielding the expected cost savings, and
- GSK failed to disclose that its financial statements contained material errors.
As a result of these alleged misrepresentations, GSK’s stock price was artificially inflated, causing investors to suffer significant losses when the truth was revealed.
Impact on Individual Investors
If you invested in GSK securities between December 19, 2020, and March 24, 2025, and suffered losses, you may be able to recover your investment. The class action lawsuit seeks to represent a large group of investors who have been harmed by GSK’s alleged securities fraud. By joining the lawsuit, you may be able to hold GSK accountable for its actions and potentially recover your losses.
Impact on the World
The securities fraud allegations against GSK have far-reaching consequences. Investors rely on accurate and timely information when making investment decisions. When companies like GSK misrepresent their financial condition and business operations, it can lead to a lack of confidence in the entire market. This can result in a decrease in trading activity and increased volatility, which can negatively impact other companies and the economy as a whole.
Conclusion
The securities fraud class action lawsuit against GSK plc is an important step towards holding the Company accountable for its alleged misrepresentations. If you invested in GSK securities between December 19, 2020, and March 24, 2025, and suffered losses, you may be able to recover your investment by joining the class action lawsuit. The lawsuit seeks to represent a large group of investors who have been harmed by GSK’s actions. Additionally, the allegations against GSK highlight the importance of accurate and timely disclosures in the investment community and the negative consequences that can result from a lack of transparency.
For more information about the GSK securities fraud class action lawsuit or to discuss your investment losses, please contact Glancy Prongay & Murray LLP at 310-201-9150 or contact the firm online at [email protected].
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules. Readers are cautioned that prior results do not guarantee a similar outcome.
